Cortexin Protocol: Complete Cycling & Dosing Guide

Cortexin Protocol: Complete Cycling & Dosing Guide

Overview

Cortexin is a polypeptide neuropeptide complex derived from bovine or porcine cerebral cortex tissue. It functions as a nootropic and neuroprotective agent that has been used clinically across Russia and Eastern Europe for cognitive impairment, neurological rehabilitation, and brain injury recovery. The compound works through multiple mechanisms: activation of neurotrophic factors (BDNF, NGF), modulation of GABAergic and glutamatergic neurotransmission, antioxidant activity, promotion of neuronal DNA repair, and antiapoptotic effects.

Cortexin is administered exclusively via intramuscular injection at a standard dose of 10 mg once daily. The typical therapeutic window ranges from $40–$120 per month depending on supply source and region.

Important Disclaimer: This guide is educational content only and does not constitute medical advice. Cortexin is a prescription or pharmacy-regulated product in most jurisdictions. Consult a qualified healthcare provider before using this compound, particularly if you have contraindications, allergies, or are taking other medications.

Standard Protocol

Baseline Parameters:

• Standard dose: 10 mg intramuscular injection once daily
• Standard cycle length: 10–20 days of consecutive daily administration
• Rest period: 2–4 weeks between cycles (minimum 14 days)
• Frequency: 1–3 cycles per year based on clinical indication and response
• Total annual exposure: 100–600 mg depending on cycle frequency

Classic 10-Day Cycle (Entry-Level)

This is the most commonly reported protocol in human studies for cognitive support, post-COVID recovery, and general neuroprotection:

• Days 1–10: 10 mg IM once daily (preferably morning, before 2 PM)
• Days 11–24: Rest/washout period (no injection)
• Total dose: 100 mg
• Timeline to peak effect: 5–7 days into the cycle

Extended 20-Day Cycle (Enhanced Response)

Used for more severe cognitive impairment, traumatic brain injury recovery, or neurological rehabilitation:

• Days 1–20: 10 mg IM once daily
• Days 21–35: Rest/washout period
• Total dose: 200 mg
• Timeline to peak effect: 10–14 days into the cycle
• Note: Literature suggests dose-dependent improvements with 20 mg protocols; however, this requires splitting the standard 10 mg vial or sourcing 20 mg formulations (less common in Western markets)

Repeated Cycle Protocol (Multi-Cycle Approach)

For sustained benefits, particularly in mood, sleep, and cognitive domains:

• Cycle 1: Days 1–10 (10 mg daily)
• Rest: Days 11–24 (2 weeks)
• Cycle 2: Days 25–34 (10 mg daily)
• Rest: Days 35–48 (2 weeks)
• Cycle 3: Days 49–58 (10 mg daily, optional based on response)
• Final rest: Days 59+ (minimum 4 weeks before reinitiating)

This multi-cycle approach has been shown in studies to produce larger improvements in mood, depression scores, and sleep quality than single-cycle protocols.

Goal-Specific Protocols

Protocol A: Cognitive Enhancement & Post-COVID Brain Fog

Indication: Attention deficits, memory impairment, executive dysfunction, post-COVID cognitive complaints

Cycle Structure:

• Duration: 20 days of daily injection
• Dose: 10 mg IM once daily
• Timing: Morning administration (7–10 AM preferred)
• Rest period: 21 days minimum before repeat cycle
• Frequency: 2–3 cycles per year

Adjunct Support:

• Stack with alpha-GPC (600 mg daily) or CDP-choline (1200 mg daily) for synergistic BDNF activation
• Time stacking compounds to coincide with Cortexin administration (same morning window)
• Ensure adequate sleep; Cortexin efficacy is reduced in chronically sleep-deprived individuals

Expected outcomes timeline:

• Days 5–7: Improved concentration, reduced mental fatigue
• Days 10–12: Measurable improvements in executive function and working memory
• Days 15–20: Peak effect; auditory-verbal memory improvements most pronounced
• Post-cycle (weeks 2–4): Benefits begin to plateau or gradually decline

Protocol B: Traumatic Brain Injury & Acute Neurological Recovery

Indication: TBI with focal neurological deficits, acute stroke, perinatal CNS injury, acute neurological insult

Cycle Structure:

• Duration: 10 days of daily injection (initiate as early as possible post-injury)
• Dose: 10 mg IM once daily
• Timing: Morning administration
• Rest period: 14–21 days
• Frequency: Repeat every 3–4 weeks for 2–3 cycles during acute recovery window (first 3 months post-injury)

Critical notes:

• Cortexin has strongest evidence for accelerating EEG normalization and focal neurological symptom reduction in TBI contexts
• Initiation within 48–72 hours of injury may enhance neuroprotection
• Early verticalization (standing/mobilization) combined with Cortexin shows additive benefits in stroke recovery studies
• Not a replacement for standard neurorehabilitation; use as adjunct only

Expected outcomes timeline:

• Days 3–5: Reduction in neurological symptom severity (p<0.001 vs. standard therapy alone)
• Days 7–10: EEG normalization markers begin appearing
• Post-cycle (weeks 2–3): Continued incremental improvement in motor and neurological function

Protocol C: Mood, Anxiety & Depression Support

Indication: Depression, anxiety, emotional lability, asthenic symptoms, mood dysregulation

Cycle Structure:

• Duration: 10 days of daily injection
• Dose: 10 mg IM once daily
• Timing: Morning administration (critical—late-day dosing may cause agitation/sleep disruption)
• Rest period: 21 days
• Frequency: 2–3 cycles back-to-back for first month, then 1–2 cycles per quarter for maintenance
• Important: Single 10-day cycles show modest antidepressant/anxiolytic effects; repeated cycles (2–3 within 4–6 weeks) show substantially larger mood improvements

Adjunct Stack:

• Combine with adjunctive antidepressants (SSRIs, SNRIs) for synergistic effect
• Studies show cortexin + antidepressants produce greater MADRS score reduction than antidepressants alone
• Do NOT use as monotherapy for clinical depression without psychiatric oversight

Expected outcomes timeline:

• Days 1–3: No observable mood change; possible placebo response
• Days 5–7: Subtle improvements in emotional resilience and social engagement
• Days 8–10: Larger improvements in depression scores (most prominent after 2nd or 3rd consecutive cycle)
• Post-cycle (weeks 2–3): Benefits plateau; repeat cycle needed for continued improvement

Protocol D: Sleep Disturbance & Insomnia

Indication: Chronic insomnia, sleep fragmentation, poor sleep quality, asthenia-related sleep dysfunction

Cycle Structure:

• Duration: 10 days of daily injection (some studies suggest 20 mg may show superior sleep effect, but standard formulation is 10 mg)
• Dose: 10 mg IM once daily
• Timing: Morning administration (7–9 AM); never after 2 PM due to potential CNS stimulation
• Rest period: 21 days
• Frequency: 2–3 cycles per year; sleep benefits are dose-dependent and larger at higher doses

Protocol variation for resistant insomnia:

• If available in your region, 20 mg protocols show greater sleep-stage normalization than 10 mg
• Current Western market availability of 20 mg single-dose vials is limited
• Standard workaround: Some practitioners administer 10 mg IM in morning + 10 mg IM in afternoon during first 5 days of cycle only (not standard protocol but reported in practice)

Expected outcomes timeline:

• Days 1–3: Minimal change in sleep
• Days 4–7: Reduction in sleep onset latency, fewer middle-of-night awakenings
• Days 8–10: Improved sleep consolidation; benefits often persist 2–4 weeks post-cycle
• Post-cycle (weeks 3–4): Sleep benefits begin declining; repeat cycle recommended at week 4–5 if continued sleep support needed

Protocol E: Anti-Inflammatory & Post-Viral Recovery

Indication: Post-COVID syndrome, chronic inflammation, neuroinflammation, elevated pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)

Cycle Structure:

• Duration: 10 days of daily injection
• Dose: 10 mg IM once daily
• Timing: Morning or early afternoon
• Rest period: 21–28 days
• Frequency: 2–3 cycles per treatment course (for acute post-viral conditions)

Biomarker monitoring:

• Measure baseline TNF-α, IL-1β, IL-6 before cycle 1 if possible
• Retest at end of cycle 1 (day 10) and after 2-week rest (day 24)
• Studies show 1.4–1.5-fold reductions in pro-inflammatory cytokines
• Antioxidant markers (total antioxidant status) also improve measurably

Expected outcomes timeline:

• Days 5–7: Cytokine levels begin declining
• Days 10–14: Peak anti-inflammatory effect; measurable biomarker improvements
• Post-cycle (weeks 2–3): Anti-inflammatory benefits persist during rest period

How to Administer Step-by-Step

Equipment needed:

• Cortexin vial (10 mg powder form—most common Western formulation)
• Sterile 0.9% sodium chloride (normal saline) for reconstitution, OR sterile water for injection
• 3 mL syringe with 25–27 gauge needle (for reconstitution)
• 1 mL syringe with 25–27 gauge needle (for intramuscular injection)
• Alcohol prep pads (70% isopropyl alcohol)
• Sharps disposal container

Reconstitution procedure:

1. Remove Cortexin vial from refrigerated storage (2–8°C).
2. Wipe the rubber septum of the vial with an alcohol prep pad; allow to air-dry (30 seconds minimum).
3. Draw 1–1.5 mL of sterile 0.9% sodium chloride or sterile water into the 3 mL syringe.
4. Insert the syringe needle through the vial septum at a slight angle.
5. Inject the saline slowly into the vial, directing the stream against the vial wall (not directly onto the powder).
6. Remove the syringe and needle.
7. Gently swirl the vial (do NOT shake vigorously, as this can denature peptides) for 30–60 seconds until the powder is completely dissolved.
8. The solution should be clear or slightly opalescent. If cloudiness persists or particles remain, discard and use a fresh vial.
9. Allow to sit for 1–2 minutes before drawing up for injection.
10. Draw exactly 1 mL of reconstituted Cortexin (10 mg) into the 1 mL syringe using a fresh needle.

Intramuscular injection procedure:

1. Choose injection site: gluteus medius (upper-outer quadrant of buttock) is standard; alternate sites between daily injections to minimize local reaction.
2. Alternative sites: deltoid muscle or vastus lateralis (mid-outer thigh) are acceptable but less common.
3. Wipe the injection site with a fresh alcohol prep pad; allow to air-dry completely.
4. Stretch the skin slightly at the injection site.
5. Insert the needle at a 90-degree angle using a quick, confident motion (not slowly).
6. Once the needle is fully inserted (depth should be 3–5 cm depending on tissue depth), aspirate slightly by pulling back on the plunger to check for blood (if blood appears, withdraw and use a different site).
7. If no blood is aspirated, slowly inject the 1 mL of Cortexin solution over 3–5 seconds.
8. Withdraw the needle and immediately apply gentle pressure with an alcohol pad.
9. Do NOT massage the injection site aggressively; light pressure is sufficient.
10. Dispose of the syringe and needle in a sharps container.

Storage post-reconstitution:

• Reconstituted Cortexin should be used immediately (within 30 minutes of reconstitution preferred)
• If necessary, refrigerated reconstituted solution may remain stable for 2–4 hours, but potency declines; fresh reconstitution daily is standard practice
• Unopened Cortexin vials: store at 2–8°C (refrigerated); protect from light and freezing

Cycle Example: Week-by-Week Schedule (10-Day Standard Protocol)

Week 1:

Week 2:

Week 3–4 (Rest Period):

• Continue to monitor cognitive function, mood, sleep quality
• Benefits often persist at 50–75% of peak effect through week 3
• By week 4, some decline in benefits is typical
• Prepare for repeat cycle if running multi-cycle protocol

What to Expect: Timeline of Effects

Immediate (Injection Day 1–2):

• Local injection site reactions: mild pain, slight redness, minimal swelling
• Possible transient mild headache within 2–4 hours of injection (resolve within 24 hours)
• No systemic cognitive or mood changes expected

Short-term (Days 3–5):

• Injection site reactions typically peak and begin to resolve
• First hints of improved concentration or mental clarity
• Sleep may show minor improvements
• Mood/anxiety: no significant change yet
• Mild dizziness or lightheadedness possible (most common in elderly patients; resolve by day 3–4)

Mid-cycle (Days 6–10):

• Cognitive improvements become measurable: attention, working memory, processing speed
• Sleep quality improvements plateau (if present)
• Mood stabilization and reduced anxiety/irritability (most prominent on cycle 2–3)
• Injection site reactions almost entirely resolved by day 8–10
• Energy and fatigue levels may improve

Post-cycle (Days 11–24):

• Peak cognitive and mood effects typically occur during days 10–14 post-injection start (mid-rest period)
• Benefits gradually decline over weeks 2–4 of rest period
• By week 4, benefits decline to 30–50% of peak
• Sleep benefits may persist longer than cognitive benefits (4–6 weeks post-cycle not uncommon)

Multi-cycle improvements (Cycle 2–3):

• Mood and antidepressant effects are substantially larger on cycle 2 than cycle 1
• Cumulative benefits develop; baseline cognitive function may incrementally improve
• Sleep benefits and anti-inflammatory effects compound
• Injection site reactions typically minimal after cycle 1

Common Protocol Mistakes

**Mistake 1: Skipping Daily